Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia.
Volha V ZhukouskayaInès MannesCatherine ChaussainPeter KamenickỷChristelle AudrainAnne-Sophie LambertJérôme NevouxPhilippe WicartKarine BriotFederico Di RoccoSéverine TrabadoDominique PriéCarolina Di SommaAnnamaria ColaoCatherine AdamsbaumAnya RothenbuhlerAgnès LinglartPublished in: European journal of endocrinology (2021)
We suggest that MRI is a valuable and quantitative tool to evaluate the therapeutic response to burosumab. MRI could be an excellent alternative to standard bone radiographs for evaluation of the rachitic lesions in a clinical setting avoiding repeated exposition to ionizing radiation.